Emerging antibody therapies, such as anti-FcRn antibodies for immune thrombocytopenia and autoimmune hemolytic anemia, are expanding the therapeutic horizons in benign hematology. The gene discussed is FCGRT; the disease is autoimmune thrombocytopenic purpura.